India's drug pricing authority called for better regulation of the country's massive private healthcare industry on Friday to ensure government efforts to cut prices benefit patients.
To cut the cost of procedures such as angioplasty and knee surgery, India's National Pharmaceutical Pricing Authority (NPPA) has dramatically reduced prices of knee implants and cardiac stents in recent months.
The move has been hailed as a major effort by Indian Prime Minister Narendra Modi to make healthcare affordable, but it has been met with stiff resistance from healthcare providers.
Several hospitals across the country have hiked prices of related services which are an essential part of such surgeries - like doctors' fees and hospital stay costs - to make up for the price caps, according to industry insiders and activists.
These actions risk impeding the efforts of the NPPA, as it considers bringing more medical devices under price control with the aim of making healthcare more accessible in a country where it is still a luxury for many.
"We have to find a way to rationalise the cost of hospital care," NPPA Chairman Bhupendra Singh told Reuters. "There is no legal framework to regulate hospital charges."
India spends roughly one percent of its gross domestic product on healthcare - among the lowest in the world - this has resulted in a broken public healthcare system that few trust.
Nearly 70 percent of healthcare delivery is therefore in the hands of private players, from small clinics to large hospital chains. But this private industry is largely unregulated.
The government think-tank NITI Aayog has been pushing for further privatisation of healthcare services, which some experts have expressed concerns over, pushing instead for improvements in the public health infrastructure.
Alexander Thomas, president of the Association Healthcare Providers of India, said hospitals hiking prices after the price control measures are doing so to cover treatment costs.
Most private hospitals, he added, adhere to standards and the AHPI has also been advising its member hospitals to bring in more transparency in the billing process.
Singh said the impact of bringing down the prices of knee implants and stents had been "substantial," but more needs to be done, such as clear display of treatment costs by hospitals so patients can compare prices across providers.
The health ministry could also look at standardising the cost of certain treatments, so the prices don't vary across hospitals, Singh said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)